• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Longeveron Inc.

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    SC 13G 1 ea0204046-13gintra_long.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Longeveron Inc.

     

    (Name of Issuer)

     

    Class A common stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    54303L104

    (CUSIP Number)

     

    April 8, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.             54303L104

             
    1

    Name of Reporting Persons.

     

    Mitchell P. Kopin
    2 Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

     
    3 SEC Use Only

     

     

    4 Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5 Sole Voting Power

     

    0

    6 Shared Voting Power

     

    174,054
    7 Sole Dispositive Power

     

    0

    8 Shared Dispositive Power

     

    174,054

    9 Aggregate Amount Beneficially Owned by Each Reporting Person

     

    174,054 (see Item 4)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    ☐
    11 Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)
    12 Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 2 of 8

     

     

    CUSIP No.             54303L104

             
    1 Name of Reporting Persons.

     

    Daniel B. Asher
    2 Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

     
    3 SEC Use Only

     

     

    4 Citizenship or Place of Organization

     

    United States of America

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5

    Sole Voting Power

     

    0

    6 Shared Voting Power

     

    174,054

    7 Sole Dispositive Power

     

    0

    8 Shared Dispositive Power

     

    174,054
    9 Aggregate Amount Beneficially Owned by Each Reporting Person

     

    174,054 (see Item 4)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    ☐
    11 Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)
    12 Type of Reporting Person (See Instructions)

     

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No.             54303L104

             
    1

    Name of Reporting Persons

     

    Intracoastal Capital LLC
    2 Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐

    (b) ☐

     
    3 SEC Use Only

     

     

    4 Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5 Sole Voting Power

     

    0

    6 Shared Voting Power

     

    174,054
    7 Sole Dispositive Power

     

    0

    8 Shared Dispositive Power

     

    174,054
    9 Aggregate Amount Beneficially Owned by Each Reporting Person

     

    174,054 (see Item 4)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     

    ☐
    11 Percent of Class Represented by Amount in Row (9)

     

    4.99% (see Item 4)
    12 Type of Reporting Person (See Instructions)

     

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a) Name of Issuer

     

    Longeveron Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices

     

    1951 NW 7th Avenue, Suite 520

    Miami, Florida 33136

     

    Item 2.

     

    (a) Name of Person Filing

     

    (b) Address of Principal Business Office or, if none, Residence

     

    (c) Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d) Title of Class of Securities

     

    Class A common stock, par value $0.001 per share, of the Issuer (the “Common Stock”).

     

    (e) CUSIP Number

     

    54303L104

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4.Ownership.

     

    (a) and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on April 8, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on April 11, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 122,225 shares of Common Stock, which consisted of (i) 114,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 8,225 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 1,101,254 shares of Common Stock outstanding prior to the execution of the SPA as reported by the Issuer, plus (2) 114,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (3) 8,225 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 90,541 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 212,766 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (III) 4,286 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 429,818 shares of Common Stock.

     

    (ii) As of the close of business on April 17, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 174,054 shares of Common Stock, which consisted of (i) 160,000 shares of Common Stock held by Intracoastal and (ii) 14,054 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 3,314,020 shares of Common Stock outstanding as of April 16, 2024, as reported to the Reporting Persons by the Issuer, plus (2) 160,000 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 2 and (3) 14,054 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 38,712 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 4,286 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (III) 212,766 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by that certain Warrant Exercise and Reload Agreement dated April 16, 2024 (the “Reload Agreement”) (“Intracoastal Warrant 4”) because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (IV) 212,766 shares of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated by the Reload Agreement (“Intracoastal Warrant 5”) because Intracoastal Warrant 5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 642,584 shares of Common Stock.

     

    (c) Number of shares as to which each Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:           0          .

     

    (ii) Shared power to vote or to direct the vote:        174,054               .

     

    (iii) Sole power to dispose or to direct the disposition of             0            .

     

    (iv) Shared power to dispose or to direct the disposition of            174,054              .

     

    Page 6 of 8

     

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: April 17, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
         
      /s/ Daniel B. Asher
      Daniel B. Asher
         
      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

     

    Page 8 of 8

     

    Get the next $LGVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    SEC Filings

    See more
    • SEC Form 144 filed by Longeveron Inc.

      144 - Longeveron Inc. (0001721484) (Subject)

      5/15/25 3:20:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:11:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Longeveron Inc.

      10-Q - Longeveron Inc. (0001721484) (Filer)

      5/8/25 4:00:27 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

      SC 13G/A - Longeveron Inc. (0001721484) (Subject)

      11/14/24 4:20:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      7/26/24 4:18:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      4/17/24 4:03:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LGVN
    Financials

    Live finance-specific insights

    See more
    • Longeveron® to Attend BIO International Convention 2025

      Focus on potential partnership and strategic opportunities for the Company's stem cell therapy program for Alzheimer's diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer's disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in the peer reviewed jour

      5/20/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

      Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. "We're proud to be a Semifinalist team of X

      5/12/25 7:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Soffer Rock sold $26,750 worth of shares (21,000 units at $1.27), decreasing direct ownership by 9% to 209,034 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      6/2/25 6:00:04 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Soffer Rock sold $2,640 worth of shares (2,000 units at $1.32), decreasing direct ownership by 0.86% to 230,034 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/27/25 6:52:13 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Hare Joshua sold $7,367 worth of shares (5,250 units at $1.40), decreasing direct ownership by 0.72% to 721,796 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      5/16/25 6:00:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

      5/2/25 8:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

      2/28/25 4:04:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:29 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hashad Mohamed Wa'El Ahmed bought $24,999 worth of shares (10,638 units at $2.35), increasing direct ownership by 118% to 19,616 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soffer Rock bought $325,000 worth of shares (138,298 units at $2.35), increasing direct ownership by 197% to 208,534 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

      MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

      11/11/24 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neha Motwani Elected to Longeveron® Board of Directors

      MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte

      7/9/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

      MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar, MD, Director of the Gene and Cell Therapy Institute at Mass General Brigham, has been elected to the Longeveron Board of Directors. Dr. Hajjar is an internationally recognized scientist whose cardiac gene therapy discoveries have spurred clinical trials for heart failure, whose methodologies for cardiac-directed gene transfer are currently utilized by investigators around the world, and who was appointed as the inaugural director of the

      7/8/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Longeveron with a new price target

      ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

      12/6/24 7:54:21 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EF Hutton initiated coverage on Longeveron with a new price target

      EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

      1/5/22 10:22:40 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care